Hainan He Rui Pharmaceutical Co. Ltd.

To investigate the pharmacokinetic characteristics of a single oral administration of Iguratimod tablets (test preparation, specification: 25 mg) produced by Hainan Herui Pharmaceutical Co., Ltd. under fasting and postprandial conditions in healthy subjects and a single oral administration of Iguratimod tablets (reference preparation, trade name: Edexin®, specification: 25 mg) certified by Hainan Xiansheng Pharmaceutical Co., Ltd. under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.

To investigate the pharmacokinetic characteristics of a single oral administration of budesonide enteric-coated capsules (test preparation T, specification: 4 mg) provided by Hainan Herui Pharmaceutical Co., Ltd. under fasting and postprandial conditions in healthy subjects and a single oral administration of budesonide enteric-coated capsules (reference preparation R, trade name: Tarpeyo®, specification: 4 mg) certified by Calliditas Therapeutics AB under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.

To investigate the pharmacokinetic characteristics of a single oral administration of tacrolimus capsules (test preparation, specification: 1 mg) produced by Hainan Herui Pharmaceutical Co., Ltd. under fasting and postprandial conditions in healthy subjects and a single oral administration of tacrolimus capsules (reference preparation, trade name: Prograf®, specification: 1 mg) certified by Astellas Pharma Co. Limited under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.